Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Gram-negative bacterial peptidoglycan is a vital structural polymer located within the periplasmic space, situated between the inner cytoplasmic membrane and the outer membrane. It is composed of alternating residues of N-acetylglucosamine and N-acetylmuramic acid, which are cross-linked by pentapeptide side chains to form a resilient, mesh-like layer (Vollmer et al., 2008). The primary biological role of this molecule is to maintain cell shape and provide the mechanical strength necessary to withstand high internal osmotic pressure, thereby preventing bacterial lysis (Silhavy et al., 2010). During bacterial growth and division, the peptidoglycan layer undergoes constant remodeling, a process that is highly regulated by various enzymes. In the context of infectious disease, peptidoglycan serves as a major pathogen-associated molecular pattern (PAMP); specifically, its breakdown products (muropeptides) are recognized by host intracellular receptors like NOD1 to initiate an immune response (Girardin et al., 2003). Because peptidoglycan is unique to prokaryotes, it is the primary target for several classes of antibiotics, most notably the beta-lactams, which inhibit the transpeptidation enzymes required for its synthesis (Kohanski et al., 2010). Therapeutic challenges include the presence of the Gram-negative outer membrane, which acts as a permeability barrier, and the rapid evolution of resistance mechanisms such as beta-lactamases that degrade drugs targeting this structure.
Inhibition of peptidoglycan biosynthesis and cross-linking by targeting enzymes such as penicillin-binding proteins (PBPs) or Mur ligases.
5 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Gram-negative bacterial peptidoglycan (PGN).